ClinicalTrials.gg
CompletedNCT03089762Updated Mar 27, 2017

Intra-articular Injection in the Knee of Adipose Derived Stromal Cells and Platelet Rich Plasma for Osteoarthritis

A Phase 1 interventional study of Intra-articular injection of SVF plus PRP in Osteoarthritis, sponsored by Bioheart, Inc.. Completed. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2017-03-27.

Sponsored by Bioheart, Inc. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 5 years 1 month after the study started (first participant enrolled Feb 2012, registered Mar 2017).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
50 Years and older
Sex
All
01

Study summary

Stromal vascular fraction (SVF) can easily be obtained from a mini-lipoaspirate procedure of fat tissue and platelet rich plasma (PRP) can be obtained from peripheral blood. Evaluated the safety and preliminary efficacy of administering SVF and PRP intra-articularly into patients with osteoarthritis grade 1 and 2.

02

Conditions studied

  • Osteoarthritis

Browse trials for

03

In context

Osteoarthritis

2,977 studies on the registry are indexed under Osteoarthritis; 438 are open to participants now.

This study's enrollment of 10 is below the median of 80 across 2,241 interventional studies indexed under Osteoarthritis.

Browse Osteoarthritis studies →

Lead sponsor

Bioheart, Inc. is the lead sponsor of 9 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • patients age 50 or older who present with symptomatic primary osteoarthritis of the knee
  • daily pain for the previous 3 months
  • analgesics usage at least once a week
  • less than 30 minutes of morning stiffness
  • WOMAC score of ≤ 75 in the target knee
  • Brandt Radiographic Grading Scale of Osteoarthritis grade 1 and 2

Exclusion criteria

Exclusion Criteria:

  • evidence of secondary knee osteoarthritis
  • severe osteoarthritis (Joint space width - JSW \< 2 mm)
  • prior intra articular injections within the previous one year prior to inclusion
  • patients with systemic disease
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (actual)

Study arms

  • Experimental
    SVF and PRP

    Biological: Intra-articular injection of SVF plus PRP

Interventions

  • BiologicalIntra-articular injection of SVF plus PRP

    administering SVF and PRP intra-articularly into patients with osteoarthritis grade 1 and 2

06

What researchers measure

Primary outcomes

  1. WOMAC (Western Ontario and McMaster Universities Arthritis Index)

    Time frame: 1 year

Secondary outcomes

  1. Six minute walk distance

    Time frame: 1 year

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Bansal H, Comella K, Leon J, Verma P, Agrawal D, Koka P, Ichim T. Intra-articular injection in the knee of adipose derived stromal cells (stromal vascular fraction) and platelet rich plasma for osteoarthritis. J Transl Med. 2017 Jun 19;15(1):141. doi: 10.1186/s12967-017-1242-4. PubMed 28629466 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2012 to primary completion in Dec 2014, 34 months.

Of 35 industry-sponsored phase 1 interventional studies under Osteoarthritis, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 26. This study's 34 months is above that.

Counting every sponsor, half of 58 studies reached it within 20 months; a quarter within 9 and three quarters within 47.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 15, 2017
First posted
Mar 24, 2017
StartActual
Feb 12, 2012
Primary completionActual
Dec 30, 2014
CompletionActual
Dec 30, 2014
Last update
Mar 27, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 27, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03089762
Lead sponsor
Bioheart, Inc.
Collaborators
Anupam Hospital, RegennMed Research and Therapeutics Delhi
Responsible party
Sponsor
First posted
Mar 24, 2017
Start date
Feb 12, 2012
Primary completion
Dec 30, 2014
Completion
Dec 30, 2014
Last update
Mar 27, 2017

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion